

# First Quarter 2025 Earnings Presentation

May 13, 2025



# Forward-Looking Statements

- This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as projections of our future results of operations or of our financial condition, the potential therapeutic and commercial potential of pilavapadin (LX9211), LX9851, sotagliflozin and our other drug programs, the success of our commercialization efforts with respect to INPEFA<sup>®</sup> (sotagliflozin) and any other approved products, the results of and expected timing of the completion of ongoing and future clinical trials, the expected timing and outcome of discussions with regulatory authorities regarding such trials and any applications for approval based on such trials, our other research and development efforts, and the anticipated trends in our business.
- These forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by such forward-looking statements.
- Information identifying such important factors is contained in our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, including the sections entitled “Risk Factors,” as well as our current reports on Form 8-K, in each case filed with the Securities and Exchange Commission.
- Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

# Business Overview

---

**Mike Exton, PhD**

Director and Chief Executive Officer

## Significant strategic objectives achieved in 2025



**Exclusive worldwide  
licensing agreement  
with Novo Nordisk for  
LX9851**





**Pilavapadin (LX9211)  
PROGRESS readout  
identified de-risked dose  
to move into Phase 3  
trials (10mg)**



**Reduced debt and  
strengthened financial  
position**

**Well-positioned to continue advancing and investing in innovative R&D pipeline**

# Pilavapadin 10 mg has consistently delivered clinically meaningful pain reduction



Phase 2 results suggest clinical development plan de-risked for Phase 3

\*Pilavapadin (LX9211) 100/10 mg: included 100 mg as day 1 loading dose

\*\*Pilavapadin (LX9211) 20 mg for 7 days and then 10 mg thereafter

# Neuropathic pain: A highly prevalent chronic condition with significant unmet need

**9M** people in the U.S. living with diabetes suffer from DPNP<sup>1</sup>

**1 in 4 people in the U.S. living with diabetes suffer from DPNP. By 2035, projected that there will be 13M DPNP patients in the U.S.<sup>1</sup>**

**70%** of patients with neuropathic pain do not achieve partial pain management<sup>2</sup>

**Neuropathic pain has a significant impact on quality of life for patients and caregivers**

**60%** of DPNP patients treated go on to switch or add on therapies<sup>3</sup>

**Most patients are stuck in a cycle of trial and failure with current treatment options**

1 Includes diagnosed patients only, CDC National Diabetes Statistics Report 2024. Source: prevalence rate of DPNP in diabetics is based on primary and secondary research; Source: Clearview Analysis.  
2. Rosenberger DC, Blechschmidt V, Timmerman H, Wolff A, Treede RD. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm (Vienna). 2020 Apr;127(4):589-624. doi: 10.1007/s00702-020-02145-7. Epub 2020 Feb 8. PMID: 32036431; PMCID: PMC7148276.  
3. Veeva Compass data; based on internal Lexicon claims analysis

# HCM: A significant and underpenetrated market

**~1.1 million people**  
in the U.S. have either obstructive  
or non-obstructive HCM<sup>1</sup>

**70%**  
Diagnosed  
with oHCM

**30%**  
Diagnosed  
with nHCM

**~1%**  
Market  
penetration

**43%**  
Progressive  
heart failure



1. CVrg Market Strategies. Cardiovascular Resource Group, Oct. 2023.

## Recent understanding of HCM market underscores potential for sotagliflozin

### Sotagliflozin in HCM



Broad proposed indication for both nHCM and oHCM with potential for use alone or in combination




Once-daily oral dosing enables broad adoption with no REMS



Approved for heart failure with no observed increased risk of AFIB to date

**Sotagliflozin is well-positioned with potential for broad use in HCM if approved**

# SONATA Phase 3 study for oHCM and nHCM



Enrollment underway

Only ongoing trial to evaluate **both obstructive and non-obstructive HCM**

Potential for supplemental new drug application (sNDA) with broad label

# Strategic deal with Novo Nordisk allows LX9851 to "enter the majors"

**LX9851**

First in class, potent, selective, orally bioavailable, investigational small molecule ACSL5 inhibitor

**novo nordisk**<sup>®</sup>

Exclusive, worldwide  
license to develop,  
manufacture and  
commercialize LX9851  
in all indications



Lexicon/LX9851 positioned to benefit from Novo Nordisk size, scale and capabilities



\$75 million in upfront and near-term milestone payments; up to \$1 billion in total upfront and milestones; tiered royalties



Potential differentiation in the obesity market with shift in focus to orals, combinations and improved weight-loss maintenance

# Innovative and flexible partnership approach unlocks long-term value by augmenting Lexicon’s capabilities

## Geographical expansion through Viatris’ global capabilities

Approved



Exclusive licensing agreement for **sotagliflozin** in cardiometabolic and all other indications

All markets outside of the U.S. and Europe

\$25M upfront; eligible for up to almost \$200M in milestone payments

## Maximizing asset value with Novo’s leadership position in obesity

Pre-Clinical



Exclusive licensing agreement for **LX9851** in obesity and all other indications

Global markets

\$75M in upfront and near-term milestones; eligible for up to \$1B in aggregate upfront and milestone payments

## Unlock value globally and across multiple indications

Phase 3

### Pilavapadin

Partnership approach focused on complementing Lexicon’s leading clinical development capabilities in the neuropathic pain space with a commercial footprint that can maximize value globally, and an R&D engine that can fully realize the “pipeline in a pill”

# Financial Overview

---

**Scott Coiante**  
Chief Financial Officer

# Q1 2025 Financial Summary

\$ (in millions except per share amounts)

	As of March 31, 2025*	As of December 31, 2024
Cash, cash equivalents and short-term investments	\$194.8	\$238.0
Total assets	\$297.7	\$298.4
Total debt	\$58.6**	\$100.3

	Q1 2025	Q1 2024
Total revenues	\$1.3	\$1.1
R&D	\$15.3	\$14.4
SG&A	\$11.6	\$32.1
Total operating expenses	\$26.9	\$46.5
Net loss	(\$25.3)	(\$48.4)
Net loss per common share	(\$0.07)	(\$0.20)

\*Cash balance as of March 31, 2025 includes impact of severance payments from fourth quarter (\$7.5 million)

\*\* Excludes current portion of \$42.1 million which was repaid in April of 2025.

## 2025 Guidance reflects significantly lower operating expenses



### YTD 2025 Key Financial Highlights

- First quarter included the impact of severance payments related to the restructuring and repositioning announced and accrued in 4Q 2024.
- First quarter did not include cash impact of \$45 million upfront payment (received in April) under licensing agreement with Novo Nordisk, which was used to improve balance sheet by reducing our long-term debt.



### Full Year 2025 Operating Expenses\*

- No change to operating expense guidance
  - Total 2025 operating expenses expected to be between \$135 - \$145 million
    - R&D expected between \$100 - \$105 million
      - Excludes clinical trial costs related to Phase 3 pivotal studies of pilavapadin
    - SG&A expected between \$35 - \$40 million

\*As of May 13, 2025

# Summary

---

**Mike Exton, PhD**

Director and Chief Executive Officer

# Well-positioned with a portfolio of potential “pipelines in a pill”


*Exploring opportunities across multiple therapeutic areas*

## Pilavapadin (LX9211)\*

Diabetic Peripheral Neuropathic Pain (DPNP)

Postherpetic Neuralgia (PHN)

MS Spasticity




## Sotagliflozin

Heart Failure expansion ex-US


Additional differentiation data

Hypertrophic Cardiomyopathy (HCM)



## LX9851

Obesity/Weight Management



*Timelines are illustrative and represent potential scenarios aligned to Lexicon’s overall strategy*  
 \*Execution of trials and subsequent regulatory support would require partnership or additional funding  
 \*\* IIS: Investigator-initiated studies

# Lexicon *Lead to Succeed* strategy

Designed to drive value for all stakeholders

**Driving value  
and growth for  
Lexicon with  
opportunities  
for the most  
impact for  
patients**



# Significant number of planned catalysts through 2025

<p><b>Pilavapadin (LX9211)</b></p>	<ul style="list-style-type: none"> <li>• Diabetic Peripheral Neuropathic Pain</li> </ul>	<ul style="list-style-type: none"> <li>• Full PROGRESS data anticipated in Q3</li> <li>• End of Phase 2 meeting planned in Q3</li> <li>• Data at upcoming medical meetings</li> <li>• Partnership discussions ongoing</li> </ul>
<p><b>Sotagliflozin</b></p>	<ul style="list-style-type: none"> <li>• Hypertrophic Cardiomyopathy</li> </ul>	<ul style="list-style-type: none"> <li>• EU and LATAM sites enrolling</li> <li>• All Phase 3 study sites running by Q3</li> </ul>
<p><b>INPEFA<sup>®</sup> (sotagliflozin)</b></p>	<ul style="list-style-type: none"> <li>• Heart Failure</li> </ul>	<ul style="list-style-type: none"> <li>• Regulatory submissions by Viatris ex-U.S.</li> <li>• Regulatory process related to recent MACE data</li> </ul>
<p><b>ZYNQUISTA<sup>®</sup> (sotagliflozin)</b></p>	<ul style="list-style-type: none"> <li>• Type 1 Diabetes (with CKD)</li> </ul>	<ul style="list-style-type: none"> <li>• End of review meeting held in Q2</li> <li>• Patients continue to strongly advocate for approval</li> </ul>
<p><b>LX9851</b></p>	<ul style="list-style-type: none"> <li>• Obesity and Weight Management</li> </ul>	<ul style="list-style-type: none"> <li>• Ongoing collaboration with Novo Nordisk on IND-enabling studies</li> </ul>

# Q&A



**Mike Exton, PhD**

*Director and Chief  
Executive Officer*



**Craig Granowitz, MD, PhD**

*Senior Vice President and Chief  
Medical Officer*



**Scott Coiante**

*Chief Financial Officer*

# Thank You